Earnings Call Excerpt
Insmed Incorporated (INSM)
Q2 2008 Earnings Call Transcript
August 8, 2008 8:30 am ET
Executives
Brian Ritchie – FD
Geoff Allan – President and CEO
Kevin Tully – EVP and CFO
Presentation
Operator
Good day, ladies and gentlemen, and welcome to the second quarter 2008 Insmed Incorporated earnings conference call. My name is Lacy and I’ll be your coordinator for today. At this time, all participants are in a listen-only mode. (Operator instructions) As a reminder, this conference is being recorded for replay purposes. I would now like to turn the presentation over to your host for today’s call, Mr. Brian Ritchie with FD. Please proceed.
Brian Ritchie
Thank you, operator. Good morning, everyone. This is Brian Ritchie from FD, and welcome to Insmed’s second quarter conference call. Today, we are joined by Geoff Allan, President and CEO, and Kevin Tully, Executive Vice President and CFO. Geoff will provide a business update, followed by Kevin’s review of the financials.
Insmed issued a press release this morning containing second quarter results, which is posted on the company's Web site. If you have questions after the call or would like additional information about Insmed, please contact me at 212-850-5683. Before we proceed with the call, I would like to remind everyone that the Safe Harbor language contained in today's press release also pertains to this conference call webcast.
Please go ahead, Geoff.
Geoff Allan
Thank you, Brian. Good morning, everyone, and welcome to our second quarter conference call. Once again, I am pleased to report that significant progress continues to be achieved within both areas of our business, our follow-on biologics platform and our IPLEX program.
I’d like to begin today’s call by expounding on these positive developments. Specifically, I will address the recent INS-19 results; Insmed’s partnership with Former Chairman of the House Ways and Means Committee, Bill Thomas; our retention of RBC Capital Markets as a strategic adviser; the company’s recent meeting with NASDAQ; and, Insmed’s potential near term capital requirements.
As the company has stated in the past, Insmed continues to remain at the forefront of the evolving follow-on biologics industry, and is developing one of the most robust follow-on biologics platform in this space. As you know, we have follow-on biologics candidates in various stages of development. And with more than an estimated 250,000 patients in the US being treated for neutropenia with G-CSF and pegylated G-CSF, our two leading programs, INS-19, a follow-on of Neupogen, and INS-20 a follow-on of Neulasta, if approved, will target the market that produced sales of over $4 billion in 2007.
- To read the full transcript on Seeking Alpha, click here »
